Imprimis Pharmaceuticals Inc (IMMY)

[ronk]

So if anyone else is out there...

According to this article, IMMY is a 503a licensed pharmacy with plans to build a 503b facility.

http://www.bioworld.com/content/turing-pharma-ushers-rise-compounders-rx-alternatives

I thought, "WTF is the difference?" and the 503a operates on a much smaller scale like a corner drug store with limited human resources. 503b is a larger facility that can distribute larger quantities of compounds and ship them out

Then I thought, "Are there other companies trading publicly while operating an existing 503b compounding pharmacy?"

Google.. Google...

Holy crap! A compounding pharmacy filed with the SEC to go public? IPO and disruptive technology flying under the radar. PharMEDium is going public with the ticker PMHC!!! Woo hoo! Emerging market/disruptive technology/503b pharmacy and an early entry?

http://www.nasdaq.com/article/could-be-big-pharmedium-healthcare-files-for-a-100-million-ipo-cm515339

But alas, they were bought out before they could even go public for $2.6 billion dollars.

http://www.renaissancecapital.com/news/us-ipo-weekly-recap:-cut-the-offer-price-for-positive-returns-36766.html?utm_source=dlvr.it&utm_medium=stocktwits

IMMY has a market cap of $74.55 million dollars. I thought, "lets's divide the buyout price of a company with a 503b licensed operation by the current market cap of IMMY for a pps multiplier of things to come once the 503b facility is built."

2,600,000,000 / 74,550,000 and

34.88 is the multiplier. Anyone's welcomed to check my math.

Multiplier of 34.88 X the current pps of 7.77 = $277.01 per share.

Call me crazy but that's my target price.

And I determined that compounding pharmacies are a disruptive entity and tiny little secret in biotech because 800 pound gorillas are willing to gobble them up and keep this secret in the dark.

Good luck all! Like I said, only paying 15% tax on these shares.